Loading stock data…
KPTI
$8.77+0.46 (+5.54%)
Market ClosedLast close May 1
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Karyopharm Therapeutics Inc. in the Healthcare sector is trading at $8.77. The stock is currently 20% below its 52-week high of $10.99, remaining 31.9% above its 200-day moving average. Technical signals show neutral RSI of 58 and bearish MACD signal, explaining why KPTI maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 58) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.77
Potential Upside
5%
Whystock Fair Value$9.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Buy
Mean target$12.33+40.6%
Range$5.00 – $16.00
Fundamentals
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develop...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$215.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
42.18%
Volume
Today's trading volume
229,120
Recent News
RBC Flags Seasonal Pressures Impacting Karyopharm Therapeutics Inc. (KPTI) Short-Term Performance
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Karyopharm Therapeutics Inc. is one of the best biotech stocks on this list. TheFly reported on April 7 that RBC Capital reduced its price target on KPTI to $16 from $23 while maintaining an Outperform rating. The revision was part […]
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis, raising questions on efficacy.
Assertio (ASRT) Surges 17.9%: Is This an Indication of Further Gains?
Assertio (ASRT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index adding 0.4% and the